


## Fluorofenidone

## Chemical Properties

CAS No. :	848353-85-5
Formula:	C <sub>12</sub> H <sub>10</sub> FNO
Molecular Weight:	203.21
Appearance:	no data available
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year



## Biological Description

Description	Fluorofenidone (AKF-PD) attenuates the progression of renal interstitial fibrosis partly by suppressing NADPH oxidase and extracellular matrix (ECM) deposition via the PI3K/Akt signalling pathway. Fluorofenidone is an analogue of AMR69. Which displays equivalent lower toxicity, antifibrotic activity, and longer half-life.
Targets(IC50)	Others

## Solubility Information

Solubility	DMSO: 15 mg/mL (73.82 mM), Sonication is recommended. ( $< 1$ mg/ml refers to the product slightly soluble or insoluble)
------------	---

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	4.921 mL	24.6051 mL	49.2102 mL
5 mM	0.9842 mL	4.921 mL	9.842 mL
10 mM	0.4921 mL	2.4605 mL	4.921 mL
50 mM	0.0984 mL	0.4921 mL	0.9842 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

## Reference

Qin J, et al. Fluorofenidone inhibits nicotinamide adenine dinucleotide phosphate oxidase via PI3K/Akt pathway in the pathogenesis of renal interstitial fibrosis. *Nephrology (Carlton)*. 2013 Oct;18(10):690-9.

Lou Q, et al. Design, synthesis and antifibrotic activities of carbohydrate-modified 1-(substituted aryl)-5-trifluoromethyl-2(1H) pyridones. *Molecules*. 2012 Jan 17;17(1):884-96.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

**This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use**

Tel: 781-999-4286 E\_mail: info@targetmol.com Address: 36 Washington Street, Wellesley Hills, MA 02481